SRPT

Why Sarepta Therapeutics (SRPT) Stock Soared on Tuesday

Sarepta Therapeutics, Inc. (SRPT) Presents at RBC Capital Markets Global Healthcare Broker Conference Call - (Transcript)

Sarepta's stock is up 11% on positive data from clinical trial for Duchenne treatment

Sarepta Therapeutics' Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta's Commercial Process Material

Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Why Sarepta's Q1 Results Won't Spark a Rebound for the Beaten-Down Biotech